Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REST: Impact of Semaglutide Withdrawal on Cardiometabolic Profile
NCT07294950Phase 3Recruiting
- Sponsor
- Mount Sinai Hospital
- Start
- Feb 2026
- Primary completion
- Sep 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Mount Sinai Hospital. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07294950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294950.